Proliferative Diabetic Retinopathy (PDR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The predisposing factors of proliferative diabetic retinopathy include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision, and difficulty with color perception.
Key Targets | Integrin Alpha V, Integrin Beta 3, Vascular Endothelial Growth Factor A, DNA (Apurinic or Apyrimidinic Site) Lyase, Integrin Beta 1, Integrin Beta 5, Periostin, and Retinoid Isomerohydrolase |
Key Mechanism of Actions | Integrin Alpha V Antagonist, Integrin Beta 3 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, Integrin Beta 1 Antagonist, Integrin Beta 5 Antagonist, Periostin Inhibitor, and Retinoid Isomerohydrolase Inhibitor |
Key Routes of Administration | Intravitreal, Oral, Intraocular, Ophthalmic, and Topical |
Key Molecule Types | Small Molecule, Monoclonal Antibody, and Aptamer |
Key Companies | Apexian Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Generium, Kubota Vision Inc, Kuur Therapeutics Ltd, OcuTerra Therapeutics Inc, Oxurion NV, and Ribomic Inc |
The Proliferative Diabetic Retinopathy (PDR) pipeline drugs market research report provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) and features dormant and discontinued projects
PDR Pipeline Drugs Market - Key Targets
The targets of the PDR pipeline drugs market are Integrin Alpha V, Integrin Beta 3, Vascular Endothelial Growth Factor A, DNA (Apurinic or Apyrimidinic Site) Lyase, Integrin Beta 1, Integrin Beta 5, Periostin, and Retinoid Isomerohydrolase.
PDR Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
PDR Pipeline Drugs Market - Key Mechanism of Actions
The mechanism of actions of the PDR pipeline drugs market are Integrin Alpha V Antagonist, Integrin Beta 3 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, Integrin Beta 1 Antagonist, Integrin Beta 5 Antagonist, Periostin Inhibitor, and Retinoid Isomerohydrolase Inhibitor.
PDR Pipeline Drugs Market, by Mechanism of Actions
For more mechanism of action insights, download a free report sample
PDR Pipeline Drugs Market - Key Routes of Administration
The routes of administration in the PDR pipeline drugs market are intravitreal, oral, intraocular, ophthalmic, and topical.
PDR Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
PDR Pipeline Drugs Market - Key Molecule Types
The molecule types in the PDR pipeline drugs market are small molecule, monoclonal antibody, and aptamer.
PDR Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Competitive Landscape
Some of the key companies in the PDR pipeline drugs market are Apexian Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Generium, Kubota Vision Inc, Kuur Therapeutics Ltd, OcuTerra Therapeutics Inc, Oxurion NV, and Ribomic Inc.
PDR Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
- Reviews of pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Boehringer Ingelheim International GmbH
Generium
Kubota Vision Inc
Kuur Therapeutics Ltd
OcuTerra Therapeutics Inc
Oxurion NV
Ribomic Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the PDR pipeline drugs market?
The targets of the PDR pipeline drugs market are Integrin Alpha V, Integrin Beta 3, Vascular Endothelial Growth Factor A, DNA (Apurinic or Apyrimidinic Site) Lyase, Integrin Beta 1, Integrin Beta 5, Periostin, and Retinoid Isomerohydrolase.
-
What are the key mechanism of actions of the PDR pipeline drugs market?
The mechanism of actions of the PDR pipeline drugs market are Integrin Alpha V Antagonist, Integrin Beta 3 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, Integrin Beta 1 Antagonist, Integrin Beta 5 Antagonist, Periostin Inhibitor, and Retinoid Isomerohydrolase Inhibitor.
-
What are the key routes of administration in the PDR pipeline drugs market?
The routes of administration in the PDR pipeline drugs market are intravitreal, oral, intraocular, ophthalmic, and topical.
-
What are the key molecule types in the PDR pipeline drugs market?
The molecule types in the PDR pipeline drugs market are small molecule, monoclonal antibody, and aptamer.
-
Which are the key companies in the PDR pipeline drugs market?
Some of the key companies in the PDR pipeline drugs market are Apexian Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Generium, Kubota Vision Inc, Kuur Therapeutics Ltd, OcuTerra Therapeutics Inc, Oxurion NV, and Ribomic Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.